Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors

被引:46
作者
Eggener, Scott E.
Carver, Brett S.
Loeb, Stacy
Kondagunta, G. Varuni
Bosl, George J.
Sheinfeld, Joel
机构
[1] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, Urol Serv, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Oncol Serv, Div Solid Tumor Oncol, New York, NY 10021 USA
[3] Georgetown Univ, Sch Med, Dept Urol, Washington, DC 20057 USA
关键词
retroperitoneal lymph node dissection; salvage therapy; chemotherapy; testicular neoplasms; metastatic;
D O I
10.1002/cncr.22440
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Postchemotherapy surgery is an essential component in the management of patients with metastatic germ cell tumors (GCT). The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT. METHODS. By analyzing the institutional prospective surgical database from 1989 to 2004, 71 patients were identified who underwent RPLND after multiple chemotherapy regimens. Clinicopathologic and treatment trends were characterized, and predictors of disease-specific survival (DSS) were evaluated. RESULTS. The histologic findings at RPLND were fibrosis in 36 men (51%), GCT in 20 men (28%), and teratoma in 15 men (21%). Patients who underwent RPLND from 1989 to 1998 (n = 47), compared with patients who under-went RPLND from 1999 to 2004 (n = 24) were more likely to have GCT (36% vs 13%; P = .04). Patients who received taxane-containing chemotherapy regimens as salvage therapy had lower rates of GCT at RPLND (14% vs 42%; P = .01), higher rates of fibrosis (63% vs 39%; P = .04), and similar rates of teratoma (31% vs 33%; P = .9). The 5- and 10-year DSS rates were 74% (95% confidence interval [95% CI], 62-86%) and 70% (95% CI, 56-84%), respectively. Five-year DSS based on worst histology of RPLND and extraretroperitoneal specimens was 87% (95% CI, 75-99%) for fibrosis, 87% for teratoma (95% CI, 63-100%), and 47% for GCT (95% CI, 23-71%; P = .004). On multivariable analysis, retroperitoneal mass >= 5 cm and GCT were predictors of worse DSS (P = .03 and P = .005, respectively). CONCLUSIONS. Taxane-based salvage chemotherapeutic regimens appear to have decreased the rate of GCT at RPLND. The current data support RPLND in select patients after salvage chemotherapy, because a considerable proportion has teratoma or GCT, and the 10-year DSS rate after resection is 70%.
引用
收藏
页码:528 / 535
页数:8
相关论文
共 17 条
  • [1] LATE RELAPSE OF TESTICULAR CANCER
    BANIEL, J
    FOSTER, RS
    GONIN, R
    MESSEMER, JE
    DONOHUE, JP
    EINHORN, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) : 1170 - 1176
  • [2] Tumor marker levels in post-chemotherapy cystic masses: Clinical implications for patients with germ cell tumors
    Beck, SDW
    Patel, MI
    Sheinfeld, J
    [J]. JOURNAL OF UROLOGY, 2004, 171 (01) : 168 - 171
  • [3] Testicular germ-cell cancer
    Bosl, GJ
    Motzer, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) : 242 - 253
  • [4] Donohue J P, 1984, Cancer, V54, P2716
  • [5] Donohue J P, 1998, Semin Urol Oncol, V16, P65
  • [6] OUTCOME ANALYSIS FOR PATIENTS WITH PERSISTENT NONTERATOMATOUS GERM-CELL TUMOR IN POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTIONS
    FOX, EP
    WEATHERS, TD
    WILLIAMS, SD
    LOEHRER, PJ
    ULBRIGHT, TM
    DONOHUE, JP
    EINHORN, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) : 1294 - 1299
  • [7] Metastatic nonseminomatous germ cell tumors of the testis - Results of elective and salvage surgery for patients with residual retroperitoneal masses
    Hendry, WF
    Norman, AR
    Dearnaley, DP
    Fisher, C
    Nicholls, J
    Huddart, RA
    Horwich, A
    [J]. CANCER, 2002, 94 (06) : 1668 - 1676
  • [8] Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors
    Kondagunta, GV
    Bacik, J
    Donadio, A
    Bajorin, D
    Marion, S
    Sheinfeld, J
    Bosl, GJ
    Motzer, RJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6549 - 6555
  • [9] LOGOTHETIS CJ, 1982, CANCER, V50, P1629, DOI 10.1002/1097-0142(19821015)50:8<1629::AID-CNCR2820500828>3.0.CO
  • [10] 2-1